TPO and Thrombocytopenia: This conclusion is significant because TPO-RA drugs, such as romiplostim, eltrombopag, avatrombopag, and lusutrombopag, are currently approved by the FDA and EMA for the treatment of thrombocytopenia [23], and their mechanism is to promote megakaryocyte growth, differentiation, and platelet generation [24].